FDA Contracts For QRA Model To Determine Safe Use Levels For 26 Fragrance Allergens
This article was originally published in The Rose Sheet
Executive Summary
The ingredients at issue already must be labeled on cosmetic products in the EU due to their recognized sensitization and allergy potential. FDA expects to award the contract by the end of September, and finished work will be due to the agency within 18 months thereafter.
You may also be interested in...
US FDA Pushing For Cosmetics Industry Cooperation On Allergens, Other Priorities
The FDA’s Center for Food Safety and Applied Nutrition has a wish list for cosmetics reform legislation, but with Congress currently focused elsewhere, the agency is using its existing authority and resources to address cosmetics safety priorities while working to drive voluntary industry support.
FDA Moves Forward With Planned Cosmetic Allergy Survey, Defends Practical Utility, Statistical Power
Based on stakeholder comments, the FDA has made changes to the online questionnaire it plans to use to collect information from 1,000 consumers about adverse events they have experienced and believe were caused by allergens in cosmetic products. The agency remains confident that the pilot study will provide useful insight into cosmetic allergy prevalence in the US.
FDA Solicits Protocol For Assessing Cosmetic Ingredient Aggregate Exposure Risks
According to its May 16 notice, the agency intends to award the contract to NSF International. An FDA spokesperson said NSF already undertook related work for the agency in 2018 and has rendered similar services for the US Environmental Protection Agency.